New drug cocktail shows promise for rare head and neck cancer
NCT ID NCT07353073
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of three drugs (pucotenlimab, lenvatinib, and temozolomide) given before and after surgery for people with a rare type of melanoma in the head and neck area. The goal is to see if this approach can shrink tumors and improve outcomes. About 30 adults aged 18 to 75 with resectable tumors will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK MUCOSAL MELANOMAS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Ninth People's Hospital affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 200011, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.